Immunotherapy of triple negative breast cancer

Simple item page
dc.contributor.authorDvořák Josefcs
dc.contributor.authorRichter Igorcs
dc.contributor.authorProkš Jancs
dc.contributor.authorRozsypalová Anetacs
dc.contributor.authorGrimová Janacs
dc.date.accessioned2020-06-08T09:45:58Z
dc.date.available02-12-2020en
dc.date.available2020-06-08T09:45:58Z
dc.date.issued2019-01-01cs
dc.date.updated28-20-2020en
dc.format.extent3cs
dc.identifier.issn2464-7195cs
dc.identifier.urihttps://dspace.tul.cz/handle/15240/156238
dc.language.isoczecs
dc.publisherCurrent Media s.r.o.cs
dc.relation.ispartofOnkologická review 2019en
dc.relation.ispartofseries0cs
dc.subjecttriple negative breast cancercs
dc.subjectimmunotherapycs
dc.subjectcheck point inhibitorscs
dc.subjectatezolizumabcs
dc.titleImmunotherapy of triple negative breast canceren
dc.titleImunoterapie triple negativního karcinomu prsucs
local.citation.epage79-81cs
local.citation.spage79-81cs
local.identifier.publikace6946
local.relation.issue4cs
Files
Collections